

Nifty Futures	Level 1	Level 2	Level 3
Resistance	17,060	16,950	16,830
Support	17,145	17,200	17,300

Indices (NSE)	Close	Pts. Chg	% Chg
Nifty 50	17,107.5	119.1	0.7
Nifty Future (Mar)	17,260.0	138.4	0.8
Nifty Future (Apr)	17,167.0	138.2	0.8
Nifty Bank	39,894.7	532.8	1.4
Nifty 100	16,970.5	117.6	0.7
Nifty 500	14,411.3	94.2	0.7
Nifty Midcap 100	29,958.2	175.6	0.6

Indices (BSE)	Close	Pts. Chg	% Chg
SENSEX	58,074.7	445.7	0.8
BSE 100	17,369.7	115.8	0.7
BSE 200	7,303.8	50.0	0.7
BSE AllCap	6,583.5	43.3	0.7
BSE MidCap	23,998.7	156.6	0.7
BSE SmallCap	27,034.3	134.9	0.5

Sectoral Indices	Close	Pts. Chg	% Chg
Bankex	45,258.4	581.8	1.3
Capital Goods	34,509.2	308.3	0.9
Realty	3,155.7	-3.8	-0.1
Power	3,642.0	26.6	0.7
Oil & Gas	17,596.3	81.4	0.5
Metal	19,119.3	32.6	0.2
CD	38,062.9	587.8	1.6
Auto	27,990.4	25.5	0.1
TECK	12,791.5	-78.9	-0.6
IT	27,992.1	-236.1	-0.8
FMCG	16,151.0	-91.6	-0.6
Healthcare	21,449.0	-66.1	-0.3
India VIX	15.1	-0.9	-5.8

Exchange	Advance	Decline	Unchg
BSE	1,978.0	1,550.0	121.0
NSE	1,321.0	937.0	106.0

Volume	Current Rs (in cr)	% Chg
NSE Cash	45382.7	-3.8
BSE Cash	3300.0	0.0
NSE F&O	151157.9	-15.8

Net Inflows/Outflows (Rs in cr)	Buy	Sell	Net
FII	5900.6	7355.3	-1454.6
DII	7628.2	5682.2	1946.1

Intraday Nifty Outlook

The 50 Index witnessed a gap-up opening and after marking its intraday low of 17016 it saw incremental gains throughout the day. The index also stayed above the correction low for the 2nd consecutive day marking it as day 2 of an attempt rally, closing positive after 8 straight red trading sessions. It will be crucial that the index sees more follow-through days with the lows of 16828 remaining protected to garner more bullish strength.

Corporate News

Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively

Zydus Lifesciences Limited's subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval for Tofacitinib Tablets, 5 mg and tentative approval for Tofacitinib Tablets, 10 mg (USRLD: Xeljanz® Tablets) from the United States Food and Drug Administration (USFDA). Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Tofacitinib Tablets, 5 mg and therefore is eligible for 180 days of shared generic drug exclusivity for Tofacitinib Tablets, 5 mg. Tofacitinib is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and for the treatment of adult patients with active psoriatic arthritis. It is also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC). The drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India). Tofacitinib Tablets, 5 mg and 10 mg had annual sales of USD 900 mn in the United States (IQVIA MAT Dec. 2022). The group now has 352 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04. (Source: Business Standard)

Tata Motors Announces Price Increase for Commercial Vehicles Ahead of BS6 Phase II Emission Norms

Tata Motors, the largest commercial vehicle manufacturer in India, will be implementing a price increase of up to 5% on its commercial vehicles starting from April 1st, 2023. The decision to increase prices is a result of the company's efforts to comply with the more stringent BS6 phase II emission norms. As Tata Motors transitions its entire vehicle portfolio to meet these standards, customers and fleet owners can expect a range of cleaner, greener, and technologically superior offerings that deliver higher benefits and lower total cost of ownership. The price increase will be applied across the entire range of commercial vehicles, with the exact amount varying according to the individual model and variant. (Source: Economic Times)

Pidilite Ventures to further invest Rs. 13 crore in Finemake Technologies

Pidilite Ventures Pvt. Ltd. (PVPL) (Formerly known as Madhumala Ventures Pvt. Ltd.), a wholly owned subsidiary of the Company, has agreed to make further investment not exceeding Rs. 13 crore in tranches over a period of time, in Finemake Technologies Private Limited, (Finemake) a company working to deliver technology driven high quality home interior products. The investment would be completed, subject to fulfilment of certain conditions mentioned in the agreement, by subscribing to compulsorily convertible preference shares which would, upon conversion, and taking into consideration the existing shareholding of the Company in Finemake, shall remain less than 45% on a fully diluted basis. The nature of subscription will be cash. Subscription to its shares is being done at a mutually agreed valuation, which has not been disclosed herein due to reasons of confidentiality. (Source: Economic Times)

Morning Wealth

Nifty Top 5 Gainers	Close	Pts. Chg	% Chg
HDFCLIFE	482.8	17.5	3.8
RELIANCE	2,269.7	68.4	3.1
BAJFINANCE	5,710.1	159.3	2.9
BAJAJ-AUTO	3,905.7	100.7	2.7
TITAN	2,514.1	54.1	2.2
Nifty Top 5 Losers	Close	Pts. Chg	% Chg
HINDUNILVR	2,462.6	-48.6	-1.9
POWERGRID	223.2	-4.3	-1.9
BRITANNIA	4,264.7	-67.2	-1.6
TECHM	1,095.7	-13.3	-1.2
TCS	3,106.1	-37.2	-1.2

Int. Indices	Close	Pts. Chg	% Chg
S&P 500	4,002.9	51.3	1.3
Dow 30	32,560.6	316.0	1.0
NASDAQ	11,860.1	184.6	1.6
FTSE 100	7,536.2	132.4	1.8
DAX	15,195.3	262.0	1.7
CAC 40	7,112.9	99.8	1.4
Nikkei 225*	27,416.5	470.8	1.7
Hang Seng*	19,689.5	430.7	2.2

ADR	Close	Pts. Chg	% Chg
HDFC Bank ADR	64.6	0.9	1.3
ICICI Bank ADR	20.8	0.4	1.8
Infosys ADR	16.9	0.0	-0.2
Wipro ADR	4.5	-0.1	-1.1

Currencies	Close	Pts. Chg	% Chg
Dollar Index*	102.8	-0.1	-0.1
USD/INR	82.6	0.0	0.0
EURO/INR	88.5	0.0	0.0
USD/YEN*	132.3	1.1	0.8

Commodities	Close	Pts. Chg	% Chg
Gold (spot) Rs	58,625.0	-881.0	-1.5
Silver (spot) Rs	68420.0	-418.0	-0.6
Crude (Brent) \$*	74.8	-0.6	-0.7
Crude (WTI) \$*	69.3	1.7	2.5

*rates as at 8.25 am

Economy

12 states raise record Rs 35,800 crore through securities auction

In the largest-ever state government securities auction so far this fiscal, 12 states on Tuesday raised Rs 35,800 crore at an average annualised price of 7.74 per cent. The current drawdown is 15 per cent higher than the amount indicated for the week in the auction calendar and 66 per cent higher than the year-ago period. This is the penultimate week in the borrowing calendar for the states this fiscal. Despite increased supply, the states were forced to offer better yields to investors as the weighted average cut-off rose by 7 bps to 7.74 per cent over the past week's auction, according to an analysis by ratings agency Icra. The agency also noted that the weighted average cut-off rose by 7 bps in spite of the weighted average tenor declining mildly to 14 years from 15 years.

(Source: Business Standard)

International News

UBS on track for biggest gain since Mar 2020 post Credit Suisse takeover

UBS Group AG jumped as much as 10%, on track for its biggest gain since March 2020, as investor optimism about the takeover of its largest rival gathered pace. The Swiss firm led European banking stocks higher as fears around the stability of the finance sector eased after UBS's emergency acquisition of Credit Suisse Group AG. UBS is poised to add almost 6.6 billion Swiss francs (\$7.1 billion) to its market value since the historic deal was announced late Sunday. The government-brokered, 3 billion franc rescue was intended to put an end to a crisis of confidence at Credit Suisse and stem contagion through the global financial system that started with the collapse of Silicon Valley Bank. The deal values Credit Suisse at a fraction of its previous price, with a raft of government backstops and guarantees to help ease the pain for UBS. For UBS investors, the deal offers plenty of advantages: It's gaining valuable assets such as Credit Suisse's Swiss business and access to its roster of wealthy clients and sizeable asset base, at a rock-bottom price. It will also allow the bank to cherry pick the best talent at its rival.

(Source: Business Standard)

Major Bulk Deal (NSE)

Scrip Name	Qty	Type	Client Name	Trade Price
NO MAJOR BULK DEALS				

Major Bulk Deal (BSE)

Scrip Name	Qty	Type	Client Name	Trade Price
NO MAJOR BULK DEALS				



Morning Wealth

EVENTS CALENDAR

Monday 20-March-2023	Tuesday 21-March-2023	Wednesday 22-March-2023	Thursday 23-March-2023	Friday 24-March-2023
Results–	Results–	Results–	Results–	Results–
Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–
Global– Europe Trade Balance (Jan)	Global– U.S. Existing Home Sales (Feb)	Global– GBP CPI (YoY) (Feb) , US Fed Interest Rate Decision	Global– GBP BoE Interest Rate Decision (Mar)	Global–
27-March-2023	28-March-2023	29-March-2023	30-March-2023	31-March-2023
Results–	Results–	Results–	Results–	Results–
Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–
Global–	Global– U.S. CB Consumer Confidence	Global– US Pending Home Sales (MoM) (Feb)	Global– German CPI (YoY) (Mar) , US GDP (QoQ) (Q4)	Global– Europe CPI (YoY) (Mar), Core PCE Price Index (MoM) (Feb)
03-April-2023	04-April-2023	05-April-2023	06-April-2023	07-April-2023
Results–	Results–	Results–	Results–	Results–
Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–	Economic Indicators–
Global– U.S. ISM Manufacturing PMI	Global– U.S. JOLTs Job Openings (Feb)	Global– U.S. ADP Non-farm Employment Change (Mar) , U.S. ISM Non-Manufacturing PMI (Mar)	Global–	Global– U.S. Nonfarm Payrolls, U.S. Unemployment Rate (Mar)



Research Desk

Tel: +91 22 61596406

Institutional Sales Desk

Tel: +91 22 61596403/04/05

Disclaimer Appendix**Analyst (s) holding in the Stock : Nil****Analyst (s) Certification:**

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

General Disclaimer

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice.

Recipients of this material should rely on their own investigations and take their own professional advice. BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Corporate Office:

4th floor,
Rustom Bldg,
29, Veer Nariman Road, Fort,
Mumbai-400001
Phone- +91 22 6159 6464
Fax-+91 22 6159 6160
Website- www.bpwealth.com

Registered Office:

24/26, 1st Floor, Cama Building,
Dalal street, Fort,
Mumbai-400001

BP Equities Pvt. Ltd.
CIN No: U67120MH1997PTC107392